细胞学与手术标本中PD-L1表达与临床病理及分子特征关联
本研究评估细胞学标本用于PD-L1检测的充分性,并探索PD-L1表达与临床病理及分子特征的相关性。共纳入100例细胞学标本和165例手术标本,采用22C3 assay检测PD-L1。结果显示细胞学与手术标本PD-L1阳性率无显著差异,PD-L1阳性与基因改变显著相关,尤其与KRAS突变显著相关。
要点
- 细胞学标本PD-L1阳性率56.0%,手术标本52.1%,两者无显著差异。
- PD-L1阳性与基因改变显著相关,且与KRAS突变显著相关。
- PD-L1表达与组织学表型或其他临床病理特征无显著关联。
核心结论
- 细胞学标本在PD-L1评估方面与手术标本相当。
- PD-L1表达与KRAS突变相关,可能有助于选择免疫治疗患者。
研究设计与样本
- 研究队列包括100例细胞学标本(积液28例,细针穿刺72例)和165例手术标本(活检138例,切除27例)。
- 采用22C3 pharmDx伴随诊断 assay 进行PD-L1免疫组化检测,并按制造商说明评估染色。
主要发现
- 细胞学标本PD-L1阳性率为56.0%,手术标本为52.1%,差异无统计学意义。
- PD-L1阳性在基因改变病例中显著更常见。
- PD-L1阳性及高表达(≥50%)均与KRAS突变有统计学显著关联。
临床怎么用
- 细胞学标本可用于非小细胞肺癌PD-L1评估,与手术标本结果可比。
- PD-L1表达与KRAS突变相关,可能辅助免疫治疗患者选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Programmed cell death ligand 1 (PD-L1) expression by the 22C3 pharmDx companion assay has been validated in surgical specimens to support pembrolizumab treatment decisions for patients with non-small cell lung carcinoma (NSCLC). The aims of this study were 1) to assess the adequacy of cytologic specimens for PD-L1 evaluation and 2) to explore correlations of PD-L1 expression with clinicopathologic and molecular features. METHODS: The study cohort included 100 cytology specimens (fluid [n = 28] and fine-needle aspiration [n = 72]) and 165 surgical specimens (biopsy [n = 138] and resection [n = 27]). The PD-L1 immunohistochemistry 22C3 assay and staining assessment were performed according to the manufacturer's instructions. PD-L1 expression was correlated with patients' demographics, pathologic characteristics, and molecular alterations. RESULTS: One hundred forty-two specimens (53.6%) were positive for PD-L1 expression (≥1%). No statistically significant difference in PD-L1 expression was identified between cytologic (56.0%) and surgical specimens (52.1%). Seventy-four of 190 tested cases (38.9%) had genetic alterations. PD-L1 positivity was significantly more prevalent in cases with genetic alterations than in cases without genetic alterations. Furthermore, both PD-L1 positivity and high PD-L1 expression (≥50%) had statistically significant associations with Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations. PD-L1 expression had no significant association with histologic phenotypes or other clinicopathologic features. CONCLUSIONS: The data indicate that cytologic specimens are comparable to surgical specimens for PD-L1 evaluation. The association of PD-L1 expression with KRAS mutations may have clinical relevance in selecting patients with NSCLC for immunotherapy.
引用
- Mei P, Shilo K, Wei L, et al. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations. Cancer Cytopathol. 2019. PMID: 31025831. doi:10.1002/cncy.22140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。